Susan B. Washer - Feb 18, 2022 Form 4 Insider Report for APPLIED GENETIC TECHNOLOGIES CORP (AGTC)

Role
President and CEO, Director
Signature
/s/ Stacie Aarestad, Attorney-in-fact
Stock symbol
AGTC
Transactions as of
Feb 18, 2022
Transactions value $
$20,549
Form type
4
Date filed
2/22/2022, 08:34 PM
Previous filing
Nov 3, 2021
Next filing
Aug 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGTC Common Stock Options Exercise $42.2K +121K +373.81% $0.35 153K Feb 18, 2022 Direct
transaction AGTC Common Stock Sale -$21.7K -9.95K -6.5% $2.18 143K Feb 18, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGTC Stock Option (right to buy) Options Exercise $0 -121K -100% $0.00* 0 Feb 18, 2022 Common Stock 121K $0.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.15 to $2.22, inclusive.
F2 Option is fully-vested and was exercisable for shares of common stock at any time until the expiration of the option at the holder's election.

Remarks:

The reporting person undertakes to provide to Applied Genetic Technologies Corporation, any security holder of Applied Genetic Technologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 above.